Kim Seng Thai Medicine-B (02511) cooperates with the Chinese Academy of Medical Sciences Institute of Pharmaceutical Biotechnology to explore the potential of innovative drug metabolism and renal benefits.

Wisdom Financial News APP reports that Junshengtai Pharmaceuticals-B (02511) announced that its wholly-owned subsidiary, Shenzhen Junshengtai Biotechnology Co., Ltd., has partnered with the Institute of Biotechnology at the Chinese Academy of Medical Sciences (CAMS) to evaluate the therapeutic potential of the group's core product HTD1801 for the treatment of diabetes with chronic kidney disease (CKD with T2DM). The project has recently been approved by CAMS. Based on this project, both parties will carry out innovative drug mechanism and clinical research focusing on diabetes and CKD indications, aiming to explore innovative treatment solutions with comprehensive intervention value.